Search results
Showing 151 to 165 of 311 results for breast cancer
Etirinotecan pegol for treating breast cancer with brain metastases [ID881]
Discontinued Reference number: GID-TA10066
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer in adults.
This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]
Discontinued Reference number: GID-TA10570
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.
Awaiting development Reference number: GID-TA10896 Expected publication date: TBC
In development Reference number: GID-TA11342 Expected publication date: TBC
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
Discontinued Reference number: GID-TA10295
Digital AI tools in histopathology (breast and prostate cancer)
Awaiting development Reference number: GID-HTE10087 Expected publication date: TBC
Discontinued Reference number: GID-TA10591
Awaiting development Reference number: GID-TA11487 Expected publication date: TBC
Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]
Discontinued Reference number: GID-TA10309
Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)
Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.
Awaiting development Reference number: GID-TA11686 Expected publication date: TBC
In development Reference number: GID-TA11658 Expected publication date: TBC